Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 772, Issue -, Pages 33-42Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2015.12.038
Keywords
Curcumin; Invasive fungal infections; Antifungal activity; Anticancer activity
Categories
Funding
- Anhui Provincial traditional Chinese Medicine Scientific Research Project [2014zy79]
- Scientific Research Project of Social Develop-ment Plans of Hefei City [25(46)]
Ask authors/readers for more resources
Invasive fungal infections (IFI) are important complications of cancer, and they have become a major cause of morbidity and mortality in cancer patients. Effective anti -infection therapy is necessary to inhibit significant deterioration from these infections. However, they are difficult to treat, and increasing antifungal drug resistance often leads to a relapse. Curcumin, a natural component that is isolated from the rhizome of Curcuma longa plants, has attracted great interest among many scientists studying solid cancers over the last half century. Interestingly, curcumin provides an ideal alternative to current therapies because of its relatively safe profile, even at high doses. To date, curcumin's potent antifungal activity against different strains of Candida, Cryptococcus, Aspergillus, Trichosporon and Paracoccidioides have been reported, indicating that curcumin anticancer drugs may also possess an antifungal role, helping cancer patients to resist IFI complications. The aim of this review is to discuss curcumin's dual pharmacological activities regarding its applications as a natural anticancer and antifungal agent. These dual pharmacological activities are expected to lead to clinical trials and to improve infection survival among cancer patients. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available